

Thierry Dervieux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4215054/publications.pdf>

Version: 2024-02-01

46
papers

2,519
citations

236925

25
h-index

233421

45
g-index

46
all docs

46
docs citations

46
times ranked

2469
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2766-2774. | 6.7 | 312 |
| 2 | Pharmacogenetics and cancer therapy. <i>Nature Reviews Cancer</i> , 2001, 1, 99-108. | 28.4 | 227 |
| 3 | Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. <i>Clinical Chemistry</i> , 1998, 44, 551-555. | 3.2 | 193 |
| 4 | Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 3095-3103. | 6.7 | 188 |
| 5 | Contribution of common polymorphisms in reduced folate carrier and 5,6-methyltetrahydropteroylglutamate synthetase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 733-739. | 5.7 | 155 |
| 6 | Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 607-612. | 6.7 | 148 |
| 7 | Liquid Chromatography-Tandem Mass Spectrometry Analysis of Erythrocyte Thiopurine Nucleotides and Effect of Thiopurine Methyltransferase Gene Variants on These Metabolites in Patients Receiving Azathioprine/6-Mercaptopurine Therapy. <i>Clinical Chemistry</i> , 2005, 51, 2074-2084. | 3.2 | 105 |
| 8 | Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 605-611. | 5.7 | 92 |
| 9 | De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. <i>Blood</i> , 2002, 100, 1240-1247. | 1.4 | 87 |
| 10 | HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis. <i>Clinical Chemistry</i> , 2003, 49, 1632-1641. | 3.2 | 87 |
| 11 | Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. <i>Rheumatology</i> , 2010, 49, 2337-2345. | 1.9 | 71 |
| 12 | Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 140, 334-341. | 2.8 | 69 |
| 13 | Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 4040-4047. | 6.7 | 66 |
| 14 | Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. <i>Lupus Science and Medicine</i> , 2014, 1, e000056. | 2.7 | 65 |
| 15 | Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 935-944. | 1.5 | 51 |
| 16 | Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005, 573, 180-194. | 1.0 | 47 |
| 17 | Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. <i>Clinical Chemistry</i> , 1998, 44, 2511-2515. | 3.2 | 42 |
| 18 | Cell-bound complement activation products in SLE. <i>Lupus Science and Medicine</i> , 2017, 4, e000236. | 2.7 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 1-9. | 1.5 | 38 |
| 20 | Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood. <i>Future Science OA</i> , 2015, 1, FSO26. | 1.9 | 35 |
| 21 | Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2019, 6, e000318. | 2.7 | 34 |
| 22 | Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatologyâ€“Classified Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 78-88. | 5.6 | 33 |
| 23 | Overview of the pharmacoeconomics of pharmacogenetics. <i>Pharmacogenomics</i> , 2006, 7, 1175-1184. | 1.3 | 32 |
| 24 | Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as antinuclear antibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e36-e36. | 0.9 | 27 |
| 25 | Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 908-910. | 0.9 | 25 |
| 26 | Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. <i>Lupus Science and Medicine</i> , 2016, 3, e000127. | 2.7 | 24 |
| 27 | Phenotype Determination of Thiopurine Methyltransferase in Erythrocytes by HPLC. <i>Clinical Chemistry</i> , 2001, 47, 956-958. | 3.2 | 23 |
| 28 | High-performance liquid chromatographic determination of methyl 6-mercaptopurine nucleotides (Me6-MPN) in red blood cells: analysis of Me6-MPN per se or Me6-MPN derivative?. <i>Biomedical Applications</i> , 1999, 730, 273-274. | 1.7 | 19 |
| 29 | Antibodies targeting protein-arginine deiminase 4 (PAD4) demonstrate diagnostic value in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 434-436. | 0.9 | 19 |
| 30 | Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2016, 3, e000165. | 2.7 | 18 |
| 31 | Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. <i>Journal of Immunological Methods</i> , 2017, 446, 54-59. | 1.4 | 18 |
| 32 | Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018, 5, e000263. | 2.7 | 18 |
| 33 | HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. <i>Clinical Chemistry</i> , 2002, 48, 61-8. | 3.2 | 16 |
| 34 | Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 506-516. | 4.7 | 14 |
| 35 | Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases. <i>Journal of applied laboratory medicine</i> , The, 2019, 4, 40-49. | 1.3 | 13 |
| 36 | Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability. <i>Rheumatology</i> , 2009, 48, 597-598. | 1.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Detection of anti-dsDNA antibodies by computer-aided automated immunofluorescence analysis. <i>Journal of Immunological Methods</i> , 2016, 433, 17-22. | 1.4 | 10 |
| 38 | Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. <i>Lupus Science and Medicine</i> , 2019, 6, e000349. | 2.7 | 9 |
| 39 | Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , 2021, 228, 108755. | 3.2 | 9 |
| 40 | Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2017, 2017, 1-5. | 2.2 | 8 |
| 41 | Cell-bound complement activation products associate with lupus severity in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000377. | 2.7 | 7 |
| 42 | Fibroblasts from methotrexate-sensitive mice accumulate methotrexate polyglutamates but those from methotrexate-resistant mice do not. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 433-5. | 0.8 | 7 |
| 43 | Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1285-1286. | 0.9 | 5 |
| 44 | Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: Comment on the article by Stamp et al. <i>Arthritis and Rheumatism</i> , 2010, 62, 2559-2560. | 6.7 | 2 |
| 45 | Diagnostic performance of a new anti-carbamylated protein assay in rheumatic diseases. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 249-250. | 1.1 | 1 |
| 46 | Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability: reply. <i>Rheumatology</i> , 2009, 48, 1620-1620. | 1.9 | 0 |